Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
Launched by SUN YAT-SEN UNIVERSITY · Jul 24, 2012
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a treatment called temozolomide (TMZ) given after radiation therapy for patients with low-grade gliomas (LGG), which are a type of brain tumor. The goal is to see if combining these treatments can help patients live longer without their tumors progressing, while also maintaining a good quality of life. Researchers will compare this combination treatment to radiation therapy alone to determine which is more beneficial for patients who have not had their tumors completely removed.
To participate in this trial, individuals must be between 18 and 60 years old and have a specific type of brain tumor that has not been fully removed during surgery. They should also be in decent overall health, as determined by a performance score, and must be able to understand the trial and give their consent. Participants can expect regular check-ups and monitoring throughout the study to track their health and response to the treatment. It's important to know that certain people, such as those with prior treatments or specific health conditions, may not be eligible for this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: 18 years to 60 years
- • Incompletely resected supratentorial WHO II astrocytoma, oligodendroglioma or oligodendroastrocytoma
- • Karnofsky Performance Score ≥ 60
- • Adequate bone marrow, liver and renal function
- • Ability of subject to understand character and individual consequences of the clinical trial
- • Written informed consent
- Exclusion Criteria:
- • Refusal to participate the study
- • Known hypersensitivity or contraindication to temozolomide
- • Previous irradiation, prior radiosurgery or prior chemotherapy
- • Pregnant or lactating females
- • Malignant tumor other than brain tumor
- • Contraindicated for MRI examination
- • Unable to comply with the follow-up studies of this trial
About Sun Yat Sen University
Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Zhong-ping CHEN, MD, PhD
Principal Investigator
Sun Yat-sen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials